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Objective. To examine racial differences in dis- 
ease onset, extent, manifestations, and survival among 
women with scleroderma. 
Methods. A retrospective cohort study of women 
with scleroderma, diagnosed in Michigan between 1980 
and 1991, was conducted. Clinical, laboratory, and 
demographic data were abstracted from the patients' 
medical records. 
Results. A total of 514 women with scleroderma 
were identified: 117 (23%) were black and 397 (77%) 
were white. Among black women, the mean age at  
diagnosis was lower (44.5 years versus 51.5 years; P < 
0.001) and diffuse disease was more common (49.6% 
versus 24.9%; P < 0.001) than among white women. The 
overall incidence of scleroderma was 14.1 per million 
per year: 22.5 per million per year in black women 
versus 12.8 per million per year in white women (P < 
0.001). Pericarditis (P = 0.009), pulmonary hyperten- 
sion (P < 0.001), pleural effusions (P = 0.01), myositis 
(P = 0.02), and an erythrocyte sedimentation rate >40 
mmlhour (P < 0.001) were more frequent among black 
women, while white women were more likely to have 
digital infarctions (P < 0.001). Survival at 7 years from 
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diagnosis was 72.5% among black women and 77.6% 
among white women. Age-adjusted survival was signifi- 
cantly reduced among black women (P = 0.033), most 
likely because of increased diffuse involvement. Survival 
among those with renal or pulmonary involvement was 
also significantly reduced. 
Conclusion. Black women with scleroderma were 
significantly more likely than white women to develop 
diffuse disease, be diagnosed at a younger age, have a 
higher incidence of inflammatory features, and have a 
worse age-adjusted survival rate. 
Scleroderma is an uncommon connective tissue 
disease that is characterized by variable degrees of 
fibrosis within the skin and internal organs. Previous 
epidemiologic studies have provided estimates of inci- 
dence, prevalence, and mortality, and have identified the 
various clinical and laboratory manifestations that dis- 
tinguish the diffuse and limited scleroderma subtypes 
(1,2). In addition, some investigators have suggested 
important differences between black and white women 
with regard to incidence, mortality, case fatality, and 
extent of disease manifestations (3-5). However, few 
studies have contained sufficient numbers of both black 
and white women to completely identify and confirm 
these observations. 
As part of a population-based case-control study 
to identify potential risk factors among women with 
scleroderma, we recruited a large, racially diverse cohort 
of women with scleroderma in Michigan (6). During 
review of their medical records, 74 clinical and labora- 
tory parameters were recorded, as well as demographic 
information, date of diagnosis, and date of death or last 
followup examination. These data enabled us to examine 
racial differences in age at diagnosis, extent of disease, 
clinical manifestations, incidence of disease, and sur- 
vival. 
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Table 1. Sources of eligible patients with scleroderma in Michigan 
Source 
No. of patients 
identified by 
each source 
University of Michigan 
Wayne State University 
Physician referral 
United Scleroderma Foundation 










* 141 women were identified by 2 sources, 72 by 3 sources, and 17 by 
4 sources. 
PATIENTS AND METHODS 
Patients. We attempted to identify all women 18 years 
or older who were diagnosed with scleroderma in Michigan 
between January 1, 1980 and December 31, 1991. Patients 
were recruited from 5 different sources: 1) a comprehensive 
hospital discharge diagnosis database (Health Care Investment 
Analysts, Inc. [HCIA], Ann Arbor, Michigan), 2) the Univer- 
sity of Michigan Hospitals database, 3) Wayne State University 
Hospitals database, 4) inquiries to all Michigan rheumatolo- 
gists, and 5 )  solicitation by mail of the members of the 
Southeast Michigan chapter of the United Scleroderma 
Foundation. 
HCIA initially contacted 201 hospitals and requested 
that consent forms be sent to all potentially eligible women. 
Among these hospitals, 128 (64%) agreed to participate (rep- 
resenting 78% of potential subjects), 49 (24%) declined due to 
staffing shortages, and 24 (12%) had closed or were operating 
under another hospital system. The University of Michigan 
and Wayne State hospital databases allowed chart reviews of 
all potentially eligible women. Of 109 Michigan rheumatolo- 
gists, 76 (70%) agreed to mail consent forms to their poten- 
tially eligible patients. Finally, the United Scleroderma Foun- 
dation of Michigan mailed consent forms to all of their 
members. The contributions of each source to the final patient 
pool are shown in Table 1. 
A precise estimate of the response rate cannot be 
calculated because of the constraints on patient anonymity 
required by most patient sources. However, the response rate 
to patient mailings was estimated to be between 75% and 80% 
after adjusting for duplicate names, ineligible patients, and 
incorrect mailing addresses. Of those who returned forms, 
93% agreed to participate. A capture-recapture analysis (7), 
which estimates a population size based on the overlap of cases 
identified from different sources, yielded an estimated capture 
proportion of 81% when stratified by geographic region (De- 
troit metropolitan area versus the rest of the state). 
Data collection. Patient charts were abstracted by study 
personnel using a coding form containing 74 clinical and 
laboratory variables (6). Each of these variables was recorded 
as normal, abnormal, or not performed. A given disease 
manifestation was coded as present if it appeared at any time 
in the charts. All abstractors were trained by study rheuma- 
tologists and were given several practice charts to review while 
in the presence of the rheumatologist. Interrater reliability was 
evaluated by requiring all abstractors to review the same 5 
charts. Any discrepancies or omissions were discussed with the 
abstractors. The final diagnosis and eligibility were determined 
by 1 of the study rheumatologists after reviewing the informa- 
tion on the abstraction form. If the diagnosis, eligibility, or 
other elements of the clinical data were unclear, additional 
chart sources were sought and/or the patient’s physician was 
contacted by telephone. The date of diagnosis was defined as 
the date scleroderma was first mentioned by the attending 
physician. 
Eligible women either met the American College of 
Rheumatology (ACR; formerly, the American Rheumatism 
Association) criteria for definite scleroderma (8), or were 
judged to have had probable scleroderma (sclerodactyly and 1 
or more of the following: calcinosis, Raynaud’s phenomenon, 
esophageal dysmotility, and telangiectasias [CREST]). Eligible 
patients were then further classified as having diffuse sclero- 
derma (labeled as such in the chart, or if sclerodermatous skin 
changes in the trunk, thighs, or upper arms were described), 
limited scleroderma (labeled in the chart as limited or CREST, 
or found to have Raynaud’s phenomenon, sclerodactyly, and 
telangiectasias), or unspecified scleroderma (labeled as sclero- 
derma in the chart, but with insufficient information regarding 
skin involvement to distinguish between diffuse and limited 
involvement). 
The data abstracted from the charts were also used to 
identify internal organ system involvement. Renal involvement 
was defined as a serum creatinine level of 21.8 mgidl or a 
history of hypertensive crisis. Pulmonary involvement con- 
sisted of pulmonary fibrosis (defined as fibrosis on a chest 
radiograph) or pulmonary hypertension. Gastrointestinal in- 
volvement was considered to be present if either esophageal 
dysmotility or malabsorption was documented. Myositis was 
considered to be present if labeled as such in the chart and 
accompanied by an elevated serum creatine phosphokinase 
(CPK) level. Cardiac involvement was not assessed. 
To ensure accuracy in the chart abstraction process, 
approximately two-thirds of the eligible cases were re- 
abstracted by a different member of the study team. Most of 
the reabstracted charts were from the University of Michigan 
and Wayne State University Hospitals. As a result of this 
effort, 2 patients were reclassified as ineligible because a 
diagnosis date was found prior to 1980, 46 cases of probable 
scleroderma were reclassified as definite scleroderma, pulmo- 
nary hypertension was identified in 4 additional patients, and 
pulmonary fibrosis was identified in 11 others. Many additional 
minor laboratory and physical features were found on 
reabstraction. 
Statistical analysis. Statistical tests for equality of 
proportions were performed using standard chi-square analy- 
ses. Since many hospitals did not have computerized patient 
records prior to 1985, patients diagnosed during that period 
were usually identified only if they were alive in the later 1980s. 
Therefore, because of more complete ascertainment of cases, 
and to avoid selection of patients with longer durations of 
clinical disease, incidence and survival estimates were based 
only on those cases diagnosed between 1985 and 1991. 
Incidence (technically, incidence density), expressed 
per million women per year, was calculated as 
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No. of cases diagnosed between 1985 and 1991 
(7 years X no. of women age 18 or older in Michigan)/lO' ' 
The denominator was obtained from 1990 census figures. Age- 
and race-specific incidence estimates were calculated using the 
respective subsets of the 1990 census. Confidence intervals 
(CI) for the true incidences were obtained by assuming that the 
number of incident cases follows a binomial distribution. Given 
that case ascertainment in the state was not complete, the 
incidence estimates represent lower bound estimates. 
Survival time was defined as the time from diagnosis 
until death, with the date of death obtained from the medical 
record and/or death certificate. For patients still alive, the 
censoring time was the date of the telephone interview for 
those patients who participated in the interview required for 
the case-control study, and the last date of followup recorded 
in the current medical record for those who did not. For 
patients with incomplete vital status information, a commercial 
data retrieval company (Equifax, McLean, VA) was employed 
to obtain last known date alive or date of death. 
Survival probabilities were estimated by the method of 
Kaplan and Meier (9). All-cause mortality was the variable 
used, because an additional analysis of our study population 
showed that death certificates failed to mention scleroderma as 
an underlying or contributory cause in -35% of cases (10). 
Expected survival probabilities for age- and race-matched 
Michigan women were calculated using published hazard 
figures, by age and race, for the Michigan female population 
(1 1). Survival time comparisons, adjusted for age at diagnosis, 
were performed using Cox proportional hazards regression 
(12). Age at diagnosis was included as a continuous variable in 
all models. Interactions between age at diagnosis and race or 
organ involvement (gastrointestinal, pulmonary, renal, and 
muscle) were tested; none were statistically significant. The 
proportional hazards assumption for race, age at diagnosis, 
and organ involvement was validated using standard graphical 
methods (13). 
RESULTS 
Overall, 533 eligible women with scleroderma, 
diagnosed in Michigan between 1980 and 1991, were 
Table 2. Distribution of patients with limited, diffuse, or unspecified 
scleroderma, by race.* 
Black, White, Total, 
no. (%) no. (%) no. (%) 
Diffuse 58 (49.6) 99 (24.9) 157 (30.5) 
Limited 25 (21.4) 216 (54.4) 241 (46.9) 
Unspecified 34 (29.1) 82 (20.7) 116 (22.6) 
Total 117 (100.0) 397 (100.0) 514 (100.0) 
* Diffuse disease was defined according to skin changes in the trunk, 
thighs, or upper arms, or was labeled as diffuse by the physician. 
Limited disease was labeled by the physician as either CREST 
(calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclero- 
dactyly, telangiectasias) or as limited, or was applied to patients with 
Raynaud's phenomenonisclerodactylyitelangiectasias without dif- 
fuse involvement. The term unspecified disease was applied when 
there were insufficient chart data to determine the extent of skin 
involvement. 
Table 3. Age of patients at diagnosis, by race 
Black, White, Total, 

























































































































51.8 2 13.9 
241 (100.0) 
9 (3.7) 
. .  . ,  
identified, of whom 514 were either black or white. The 
remaining 19 women of other races or for whom race 
was unspecified (n = 11) were excluded. As previously 
described, 395 women (77%) met the ACR criteria for 
scleroderma and were considered to have definite cases, 
and 119 (23%) had sclerodactyly and at least 1 other 
CREST feature and were considered to have probable 
cases. Further classification identified 157 women 
(30.5%) with diffuse scleroderma, 241 (46.9%) with 
limited scleroderma, and 116 (22.6%) with scleroderma 
of unspecified extent (Table 2). For the incidence and 
survival analyses, the 346 patients diagnosed between 
1985 and 1991, inclusive, were included. For the other 
analyses, inclusion of the women who were diagnosed 
between 1980 and 1984 did not change the proportions, 
by race, of women with diffuse and limited disease. 
Comparison of black and white women with 
regard to the extent of scleroderma and age at diagnosis 
resulted in several notable differences. Diffuse sclero- 
derma was much more common among black women 
(49.6% versus 24.9%; P < 0.001) (Table 2), and age at 
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Figure 1. Age-specific incidence of scleroderma in Michigan women, 
1985-1991, by race. A, All scleroderma. B, Diffuse scleroderma. C, 
Limited scleroderma. Bars indicate 1 standard error above and below 
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diagnosis was also significantly lower among black women 
(mean 44.5 years versus 51.5 years; P < 0.001) (Table 3). 
When disease frequencies were stratified by age at 
diagnosis, early onset of both diffuse and limited disease 
among black women was apparent (Table 3). However, 
these values were unadjusted for population frequencies 
in each ageirace category, as were the incidence esti- 
mates reported below. 
The estimated overall incidence of scleroderma 
between 1985 and 1991 (14.1 per million per year; 95% 
CI 12.7-15.6) was comparable to previously reported 
estimates (3). However, black women (22.5 per million 
per year; 95% CI 17.4-27.6) exhibited a significantly 
higher average annual incidence of scleroderma (P  < 
0.001) than did white women (12.8 per million per year; 
95% CI 11.3-14.3). This difference was most prominent 
among women who were <54 years old (Figure 1A). 
Diffuse scleroderma was more common among 
black women at all ages, particularly in the 35-44-year- 
old age group (Figure 1B). In contrast, the age-specific 
incidences for limited scleroderma were more similar, 
except that the peak age at diagnosis for black women 
occurred earlier and the age-specific incidences among 
white women were greater at all ages over 55 years 
(Figure 1C). Consistent with previous findings, and in 
contrast to the cohort of black women, there was also a 
small group of white women who developed scleroderma 
after the age of 75 (Figures 1A and C). 
Tables 4 and 5 list the most important clinical 
features of scleroderma and their frequencies, by 
diffuse/limited status and by race, respectively. Patients 
with diffuse disease were significantly more likely to 
have pericarditis, pleural effusions, myositis/myopathy, 
and renal insufficiency, and to have experienced a 
hypertensive crisis. Raynaud's phenomenon, telangiec- 
tasias, and sicca syndrome were significantly more com- 
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Table 4. Percentage of patients (n = 514) with each disease mani- 
festation, by disease extent* 
Table 5. Percentage of patients (n = 514) with each disease mani- 
festation, by race* 
Diffuse Limited P 
Calcinosis 21.0 27.0 0.18 
Esophageal dysmotility 40.1 38.2 0.70 
Digital ulcerdpitting 52.9 53.9 0.83 
Sicca syndromet 6.4 13.3 0.03 
Pericarditis 7.6 3.3 0.05 
Pulmonary hypertension 7.6 7.5 0.95 
Pulmonary fibrosis 20.4 23.2 0.50 
Pleural effusions 26.1 15.8 0.01 
Myositishnyopathy 17.8 10.0 0.02 
Peripheral arthritis (hands) 19.1 24.9 0.18 
Renal insufficiency 15.9 8.3 0.02 
Hypertensive crisis 7.0 1.7 0.01 
Raynaud’s phenomenon 88.5 97.5 <0.001 
Telangiectasias 43.3 84.2 <0.01 
Digital infarcts 7.0 12.0 0.10 






























































* Variable scored as not present if not explicitly stated in the medical 
record. See Table 2 for definitions. 
t Sicca syndrome, Sjogren’s syndrome, or keratoconjunctivitis. 
* Variable scored as not present if not explicitly stated in the medical 
record. 
t Sicca syndrome, Sjogren’s syndrome, or keratoconjunctivitis. 
mon among those with limited disease. Calcinosis was 
noted infrequently in both groups, perhaps due to its 
being relatively less apparent on physical examination 
(Table 4). 
Among black women, pericarditis, pulmonary 
hypertension, pleural effusions, myositis/myopathy, and 
renal insufficiency were significantly more common, 
while Raynaud’s phenomenon, telangiectasias, and dig- 
ital infarcts were observed significantly more frequently 
among white women (Table 5) .  Logistic regression was 
performed to assess the effect of race adjusted for 
diffuse/limited status. Pericarditis (odds ratio [OR] = 
3.5, P = 0.012) and pulmonary hypertension (OR = 3.2, 
P = 0.007) were found significantly more frequently 
among black women, while Raynaud’s phenomenon 
(OR = 5.2, P 5 0.001), telangiectasias (OR = 2.7, P -= 
0.001), and digital infarcts (OR = 4.9, P = 0.033) were 
significantly more common among white women. 
Among the laboratory variables, anticentromere 
antibodies were significantly more frequent in women 
with limited disease. Interestingly, anti-Scl-70 (anti- 
topoisomerase I) antibodies were equally prevalent in 
both the diffuse and limited scleroderma groups. How- 
ever, a further analysis demonstrated that 3 of 13 black 
women (23.1%) considered to have limited disease had 
a positive test for anti-Scl-70 antibodies, suggesting the 
possibility of failure to appropriately characterize the 
extent of skin involvement. Consistent with the in- 
creased frequencies of myositis/myopathy previously 
noted, women with diffuse disease were also more likely 
to have an elevated CPK (Table 6). 
Black women were significantly more likely to 
have had an erythrocyte sedimentation rate (ESR) >40 
mm/hour, and to have positive anti-RNP antibodies. 
Cryoglobulinemia and an elevated CPK were also more 
common among black women, but the differences were 
not statistically significant. White women, as expected, 
were significantly more likely to have anticentromere 
antibodies than were black women (35% versus 14%) 
(Table 7). Logistic regression was again performed to 
assess the effect of race adjusted for diffuseflimited 
status. Black women were significantly more likely to 
have positive rheumatoid factor (OR = 2.3, P = 0.028) 
and to have an elevated ESR (OR = 2.8, P = 0.002). 
Overall survival at 7 years after diagnosis was 
76.5% (95% CI 70.4-82.7), and was similar among black 
Table 6. Percentage (number) of patients with abnormal laboratory 
results, by disease extent* 
Rheumatoid factor 














































* Patients without test results recorded were excluded. ESR = eryth- 
rocyte sedimentation rate; ANA = antinuclear antibody; CPK = 
creatinine phosphokinase. 







Table 7. Percentage (number) of patients with abnormal laboratory of scleroderma increased significantly with age at diag- 
results, by race* nosis (RR = 1.64 for a 10-year increase in age, 95% CI 
Black White P 1.35-2.00), and, as noted above, the mean age at diag- 
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* Patients without test results recorded were excluded. See Table 6 for 
definitions. 
women (72.5%, 95% CI 58.4-86.7) and white women 
(77.6%, 95% CI 70.7-84.4) (P = 0.455) (Figure 2A). 
However, the risk of death subsequent to the diagnosis 
1.0 IL- 
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nosis was lower for black women (44.5 years) than for 
white women (51.5 years). After adjusting for age at 
diagnosis, black women had a significantly increased risk 
of death compared with white women (RR = 1.98, 95% 
CI 1.06-3.71) (P = 0.033). Survival was also significantly 
worse among women with diffuse disease compared with 
those with limited disease (RR = 2.27, 95% CI 1.22- 
4.21) (Figure 2B). No significant race effect could be 
demonstrated after adjusting for both age at diagnosis 
and diffuse/limited status (P = 0.177). 
When compared with those women without or- 
gan system involvement (7-year survival 86.4%, 95% CI 
77.8-94.9), those with gastrointestinal, muscle, pulmo- 
nary, or renal involvement experienced decreased sur- 
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Figure 2. Kaplan-Meier survival probabilities, comparing patients 
with scleroderma according to A, race (75 blacks and 271 whites), B, 
extent of disease (110 diffuse, 166 limited, and expected rate in 
Michigan women of similar age and race as in the patient population), 
and C, internal organ involvement (146 no involvement, 115 gastroin- 
testinal, 32 myositis/myopathy, 84 pulmonary, and 41 renal). Women 
with involvement of multiple organ systems were considered redun- 
dantly in these calculations. 
0.0 
0 1 2 3 4 5 6 7 8 
Time from Diagnosis to Death (years) 
C 
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viva1 (7-year survival rates 74.4% [95% CI 64.9-83.91, 
and 52.2% [95% CI 32.8-71.51, respectively) (Figure 
2C). However, after adjusting for other organ system 
involvement, as well as age at diagnosis, neither gastro- 
intestinal nor muscle involvement were significant risk 
factors for mortality (P = 0.278 and P = 0.468, respec- 
tively), while pulmonary (RR = 2.06,95% CI 1.20-3.54) 
and renal (RR = 3.65, 95% CI 2.00-6.67) involvement 
remained as significant risk factors. 
66.9% [95% CI 45.1-88.61, 60.3% [95% CI 47.1-73.61, 
DISCUSSION 
Although multiple aspects of the epidemiology of 
scleroderma have previously been described (l), rela- 
tively few publications have addressed racial differences 
in relation to clinical manifestations, incidence, and 
survival, and none has focused exclusively on women. 
Due to the relatively large size of our patient population, 
and to the relatively high proportion of black women, we 
were able to confirm and expand several earlier obser- 
vations regarding black-white differences in the manifes- 
tations of scleroderma. 
Especially interesting was the highly dispropor- 
tionate proclivity toward diffuse disease among black 
women compared with white women in our study (50% 
versus 25%). This result is consistent with the findings of 
a study by Reveille et a1 (14), in which, in a series of 156 
scleroderma patients in the US, anti-Scl-70 antibodies 
(a marker for diffuse scleroderma) were found in 37% of 
the black patients compared with only 17% of the white 
patients. Further support for the low rate of diffuse 
disease among white women can be derived from a 
report by Vayssairat et a1 (15), who found that only 8.5% 
of those in their series of 164 consecutive scleroderma 
patients (162 white; personal communication) had dif- 
fuse disease. 
The increased percentage of black women with 
diffuse disease found in our study is also notable in light 
of the study by McNeilage et al, which compared 68 
white Australian patients and 49 Thai patients with 
scleroderma (16). In that study, 15% of the Australians 
had diffuse disease compared with 100% of the Thais. 
More recently, Tan et a1 have described 19 Native 
American Choctaws with scleroderma, of whom 11 
(58%) had diffuse disease (17). Unfortunately, findings 
from the large series of Japanese patients reported by 
Tamaki et a1 (18) may not be interpreted readily because 
the investigators used a different classification system 
(19). However, with this exception, the foregoing stud- 
ies, combined with our results, suggest that white women 
have a lower incidence of diffuse disease than do women 
of color. 
Previous estimates of the incidence of sclero- 
derma, primarily among white women, have ranged from 
3.6 to 16 per million per year (4,20,21). The overall 
incidence estimated from our data, 14.1 per million per 
year, is consistent with this range. The increased inci- 
dence of scleroderma among black women contributed 
to the fact that our estimate was near the upper limit of 
the range, but it still probably underestimates the true 
incidence by roughly 20-30% because not all eligible 
women were identified and participation was not 
complete. 
When differences in the incidence of scleroderma 
between black and white women are considered, 3 
previous studies are pertinent. Medsger and Masi’s 1971 
study of a series of 86 patients (4) yielded an increase of 
-2-fold in incidence among black women. An analysis of 
US death certificates from 1969-1977 by Hochberg et a1 
also showed that age-adjusted mortality in nonwhite 
women with scleroderma was nearly twice that of white 
women (5).  In addition, a 1988 study by Steen et al, 
which assessed a cohort of 442 patients diagnosed 
between 1963 and 1982, also showed an increased inci- 
dence of scleroderma among young black women (3). 
The overall incidence of scleroderma among 
black women in Michigan was higher than in white 
women: 22.5 per million per year for black women versus 
12.8 per million per year for white women, a difference 
explained almost entirely by the excess of diffuse disease 
among black women. The age-specific incidence among 
black women exceeded that of white women at all age 
groups by 2-5-fold. The ratios were greatest among the 
25-34-year and 35-44-year age groups, which contrasts 
somewhat with the result reported by Steen et a1 (3), 
who found the greatest excess of diffuse disease in black 
women among those who were 15-24 years old. 
When grouped into diffuse and limited catego- 
ries, many of the clinical and laboratory manifestations 
noted in our study (Tables 4 and 5 )  occurred at frequen- 
cies comparable to generally accepted previous esti- 
mates (22), with some exceptions, including more calci- 
nosis than expected in the diffuse disease group and less 
esophageal dysmotility in both groups, although the 
latter may relate to the relative stringency with which 
this diagnosis was accepted during chart review. Among 
the laboratory variables for patients with diffuse disease, 
a smaller percentage than expected had anti-Scl-70 
antibodies and, conversely, a greater percentage than 
expected had anticentromere antibodies. These observa- 
tions may be partly explained by misclassification. A 
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more important factor, however, may be that the labo- 
ratory test results and clinical observations reported in 
this study reflected the judgment of the treating physi- 
cians rather than a summary from a uniformly adminis- 
tered battery of examinations. 
When clinical manifestations were considered as 
a function of race, black women were significantly more 
likely to have experienced pericarditis, pulmonary hy- 
pertension, pleural effusions, myositis/myopathy, and 
renal insufficiency. White women, largely reflecting the 
underlying greater incidence of limited disease among 
them, had significantly higher percentages of digital 
infarcts. Among the laboratory variables, black women 
were significantly more likely to have had an ESR >40 
mm/hour detected at some point during the course of 
their disease. Interestingly, 14% of black women were 
also positive for anticentromere antibodies, which sub- 
stantially exceeded the 4% found by Reveille et a1 (14), 
but only 27 blacks were tested in that study. 
Together, these observations suggest a greater 
severity of disease in black women relative to white 
women, and appear to be explained by the much higher 
frequency of diffuse disease among black women. How- 
ever, by applying logistic regression, potential race ef- 
fects, independent of diffuse/limited status, were as- 
sessed. These analyses demonstrated that black women 
had an increased risk of developing pericarditis, pulmo- 
nary hypertension, and/or an elevated ESR, and white 
women were more likely to have Raynaud’s phenome- 
non, telangiectasias, and/or digital infarcts. Some of 
these differences may be explained on the basis of ease 
of detection, e.g., telangiectasias in whites, but others 
may connote true racial differences in severity of disease 
manifestation. Pulmonary hypertension is particularly 
interesting in this regard, since both the limited and 
diffuse disease groups of black women had higher 
frequencies than those of white women. Moreover, 
although our overall frequency of pulmonary hyperten- 
sion in patients with diffuse disease was slightly higher 
than that in patients with limited disease, which con- 
trasts with previous series (22,23), when black and white 
women were examined separately, pulmonary hyperten- 
sion was more common among those with limited dis- 
ease in each group (24). 
These results would also suggest that survival 
would be expected to be decreased among black women 
in our study, as has been suggested by previous studies. 
This was first addressed by Masi and D’Angelo in a 1967 
study of 53 fatal cases of scleroderma from the Balti- 
more area (25). Those authors suggested that survival 
among blacks was decreased, especially among black 
women. In 1971, Medsger and Masi reported a series of 
86 patients (4), which, when combined with 223 sclero- 
derma patients diagnosed in Pittsburgh, again suggested 
decreased survival among blacks (26). Interestingly, 
however, 2 studies by Medsger and Masi of 358 male US 
veterans failed to demonstrate that survival among 
blacks was decreased (27,28). 
The survival data from our study support the 
notion that survival is decreased among black women, 
but only after adjustment for age at diagnosis. As in 
previous studies, survival was significantly worse among 
those women with diffuse disease and/or internal organ 
involvement (26,29-33). However, after adjusting for 
both age at diagnosis and diffuse/limited status, there 
was no longer a significant difference in survival between 
black and white women. This result suggests that the 
lack of an unadjusted survival difference between black 
and white women could be explained by racial differ- 
ences in age at onset and disease severity. Perhaps more 
significant is the fact that the combined black-white 
survival rate at 7 years (76.5%) appeared to be improved 
compared with previous estimates (27-59%) 
(4,26,28,29,33,34), although differences in disease crite- 
ria limit the validity of direct comparisons. 
Selection bias was a potential weakness of our 
study because the cases identified were neither a com- 
plete census nor a random sample of all cases in 
Michigan. Relevant in this regard is the fact that most of 
the scleroderma cases (54%) were identified from the 
University of Michigan and Wayne State University 
medical centers. In addition, because other institutions 
and practices required individual patient consent to 
release medical records, overall rates of participation 
were lower in those locations. However, the consent rate 
overall was estimated to be about 75% among eligible 
women, and no differences in consent rates by age group 
or disease severity were observed. Consent rate dispar- 
ities were identified between white women (93%) and 
black women (68%), and between patients who were 
alive (89%) and the spouse or relative of deceased 
patients (71%). The latter effect may have resulted in a 
bias toward overestimation of survival rates, but was 
probably tempered to some extent by the preponderance 
of patients being derived from the state’s tertiary refer- 
ral centers, which likely treat sicker patients with atten- 
dant lower survival rates. Bias may have been introduced 
into the analyses of clinical characteristics because of 
underascertainment during the period 1980-1984. HOW- 
ever, as mentioned above, inclusion of those patients did 
not change the proportions, by race, of women with 
diffuse and limited disease. 
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In summary, our patient cohort represents the 
largest group of black and white female scleroderma 
patients studied to date. Our data suggest that black 
women have a significantly increased incidence of dif- 
fuse scleroderma, manifest the disease at a younger age 
than white patients, are more likely to develop charac- 
teristics of aggressive disease, and, after adjusting for 
age at diagnosis, have a worse prognosis than white 
patients. Consistent with previous studies, we also dem- 
onstrate that survival in both black and white women is 
adversely influenced by internal organ involvement and 
the presence of diffuse disease. 
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